echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medical World News > Pfizer Humira biosimilars meet efficacy targets

    Pfizer Humira biosimilars meet efficacy targets

    • Last Update: 2021-02-21
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Pfizer has reported positive results for its monoclonal antibody PF-06410293, a biosimilar of the heavy bomb drug AbbVie Humira that the company is developing. Humira is an anti-TNF monoclonal antibody that has annual sales of nearly $15 billion for inflammatory disease adaptations.
    said the REFLECTIONSB538-02 study reached the main end of its trial. The American Rheumatology Society 20 (ACR20) measured the response rate of moderate to severe rheumatoid arthritis in week 12 and demonstrated that the therapeutic effect was equivalent to Humira (Adamo monoanti).
    Pfizer noted that in the past four months, PF-06410293 was the second inflammatory biosimilar to propose positive top-line results and the third to propose positive top-line results.
    Currently in the United States, the European Union and other markets have approved the drug's adaptation certificates include: rheumatoid arthritis, early idynetic arthritis, psoriasis arthritis, hyperarmline spina bifidostitis, adult Crohn's disease, pediatric Crohn's disease, ulcerative colitis, plaque psoriasis, septic sweat adenitis and staphylococcitis.
    September 2016, U.S. regulators opened the green channel for AbbVie's biologics, Amgen's Amjevita's first biosimilar. (Sina Medical News)
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.